FDA肿瘤药物咨询委员会以7:4的表决结果(两名专家弃权)通过了硫酸长春新碱脂质体注射液(Marqibo)用于治疗一种罕见的成人急性淋巴细胞白血病(ALL)。对于病情两次以上复发或是之前至少两种其他抗白血病药治疗失败且费城染色体为阴性Ph(?)的ALL患者而言,应用Marqibo治疗的获益大于风 The FDA oncology drug advisory committee adopted Marqibo for the treatment of a rare form of adult acute lymphoblastic leukemia (ALL) with a 7: 4 vote (two experts abstained). For ALL patients who relapsed more than two times or had at least two other prior antileukemic drug failures and had Philadelphia chromosome negative Ph (?), The benefit of Marqibo treatment was greater than that of the wind